An Open-Label, Multicenter, Multinational Study to Assess the Safety,Tolerability and Pharmacokinetics of Aerosolized Amikacin Delivered Via the Pulmonary Drug Delivery System (NKTR-061) in Intubated and Mechanically- Ventilated Patients With Nosocomial Pneumonia.

Trial Profile

An Open-Label, Multicenter, Multinational Study to Assess the Safety,Tolerability and Pharmacokinetics of Aerosolized Amikacin Delivered Via the Pulmonary Drug Delivery System (NKTR-061) in Intubated and Mechanically- Ventilated Patients With Nosocomial Pneumonia.

Completed
Phase of Trial: Phase II

Latest Information Update: 19 Feb 2016

At a glance

  • Drugs Amikacin (Primary)
  • Indications Gram-negative infections; Nosocomial pneumonia
  • Focus Pharmacodynamics; Pharmacokinetics
  • Sponsors Bayer
  • Most Recent Events

    • 17 Feb 2016 According to ClinicalTrials.gov record,primary end points has been revised.
    • 24 Dec 2009 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top